Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade.
The company’s stock has a 5-day price change of 57.08% and -24.72% over the past three months. LXRX shares are trading -22.75% year to date (YTD), with the 12-month market performance down to -73.09% lower. It has a 12-month low price of $0.28 and touched a high of $2.47 over the same period. LXRX has an average intraday trading volume of 6.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 56.10%, -5.65%, and -54.79% respectively.
Institutional ownership of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) shares accounts for 34.85% of the company’s 361.49M shares outstanding.
It has a market capitalization of $206.23M and a beta (3y monthly) value of 1.07. The earnings-per-share (ttm) stands at -$0.64. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.24% over the week and 13.97% over the month.
Analysts forecast that Lexicon Pharmaceuticals Inc (LXRX) will achieve an EPS of -0.1 for the current quarter, -0.1 for the next quarter and -0.36 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.12 while analysts give the company a high EPS estimate of -0.12. Comparatively, EPS for the current quarter was -0.2 a year ago. Earnings per share for the fiscal year are expected to increase by 41.27%, and 10.81% over the next financial year.
Looking at the support for the LXRX, a number of firms have released research notes about the stock. Leerink Partners stated their Market Perform rating for the stock in a research note on March 05, 2025, with the firm’s price target at $2-$1. H.C. Wainwright coverage for the Lexicon Pharmaceuticals Inc (LXRX) stock in a research note released on June 17, 2024 offered a Buy rating with a price target of $10. Leerink Partners was of a view on April 30, 2024 that the stock is Outperform, while Jefferies gave the stock Hold rating on March 07, 2023, issuing a price target of $3. Piper Sandler on their part issued Overweight rating on August 12, 2022.
